Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer

Patricia LoRusso, DO
Published: Thursday, Sep 29, 2016



Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer (TNBC).

PARP inhibitors are extremely important in BRCA-mutant disease, explains LoRusso. Studies evaluating their role in ovarian cancer have shown that PARP inhibitors can significantly increase the effectiveness of targeted agents.

Prior chemotherapy exposure, even in the adjuvant setting, can actually hinder the efficacy of PARP inhibitors by altering the BRCA mutation and thus restoring the tumor's ability to undergo homologous recombination and repair, says LoRusso.
SELECTED
LANGUAGE


Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer (TNBC).

PARP inhibitors are extremely important in BRCA-mutant disease, explains LoRusso. Studies evaluating their role in ovarian cancer have shown that PARP inhibitors can significantly increase the effectiveness of targeted agents.

Prior chemotherapy exposure, even in the adjuvant setting, can actually hinder the efficacy of PARP inhibitors by altering the BRCA mutation and thus restoring the tumor's ability to undergo homologous recombination and repair, says LoRusso.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x